(Reuters) – Novavax (NASDAQ:) Inc mentioned on Wednesday it had filed an utility with Britain’s medication regulator for the authorization of its COVID-19 vaccine amongst adolescents aged 12 and older.

Britain had in February cleared the two-dose vaccine, Nuvaxovid, to be used in adults amid a spike in circumstances fueled by the Omicron variant of the coronavirus.

Novavax’s submission consists of knowledge from a late-stage trial in america, the place the vaccine confirmed 80% efficacy amongst adolescents when Delta was the dominant variant within the nation.

The drugmaker in late January filed for emergency use authorization of its COVID-19 shot for adults in america.

The U.S. Meals and Drug Administration plans to carry a number of conferences of its exterior panel of specialists in June to debate authorization requests submitted by a number of COVID-19 vaccine producers together with Novavax.